1
|
Morgan J, DeBoer RJ, Bigirimana JB, Nguyen C, Ruhangaza D, Paciorek A, Mugabo F, Villaverde C, Nsabimana N, Bihizimana P, Umwizerwa A, Lehmann LE, Shulman LN, Shyirambere C. A Ten-Year Experience of Treating Chronic Myeloid Leukemia in Rural Rwanda: Outcomes and Insights for a Changing Landscape. JCO Glob Oncol 2022; 8:e2200131. [PMID: 35839427 PMCID: PMC9812457 DOI: 10.1200/go.22.00131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
PURPOSE In describing our ten-year experience with treating chronic myeloid leukemia (CML) as part of the Glivec Patient Assistance Program (GIPAP) in rural Rwanda, we evaluate (1) patient characteristics and treatment outcomes, (2) resource-adapted management strategies, and (3) the impact of diagnostic capacity development. METHODS We retrospectively reviewed all patients with BCR-ABL-positive CML enrolled in this GIPAP program between 2009 and 2018. Clinical data were analyzed using descriptive statistics, Kaplan-Meier methods, proportional hazards regression, and the Kruskal-Wallis test. RESULTS One hundred twenty-four patients were included. The median age at diagnosis was 34 (range 8-81) years. On imatinib, 91% achieved complete hematologic response (CHR) after a median of 49 days. Seven (6%) and 12 (11%) patients had primary and secondary imatinib resistance, respectively. The 3-year overall survival was 80% (95% CI, 72 to 87) for the cohort, with superior survival in imatinib responders compared with those with primary and secondary resistance. The median time from imatinib initiation to CHR was 59 versus 38 days (P = .040) before and after in-country diagnostic testing, whereas the median time to diagnosis (P = .056) and imatinib initiation (P = .170) was not significantly different. CONCLUSION Coupling molecular diagnostics with affordable access to imatinib within a comprehensive cancer care delivery program is a successful long-term strategy to treat CML in resource-constrained settings. Our patients are younger and have higher rates of imatinib resistance compared with historic cohorts in high-income countries. High imatinib resistance rates highlight the need for access to molecular monitoring, resistance testing, and second-generation tyrosine kinase inhibitors, as well as systems to support drug adherence. Hematologic response is an accurate resource-adapted predictor of survival in this setting. Local diagnostic capacity development has allowed for continuous, timely CML care delivery in Rwanda.
Collapse
Affiliation(s)
- Jennifer Morgan
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC,Jennifer Morgan, MD, Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Dr, CB #7305, Chapel Hill, NC 27599; e-mail:
| | - Rebecca J. DeBoer
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
| | | | | | | | - Alan Paciorek
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
| | - Fred Mugabo
- Republic of Rwanda Ministry of Health, Burera District, Rwanda
| | | | | | | | - Aline Umwizerwa
- Partners In Health/Inshuti Mu Buzima, Burera District, Rwanda
| | | | | | | |
Collapse
|
2
|
Kaang T, Dunn MG, Slone JS. Managing pediatric chronic myeloid leukemia in Africa: the Botswana experience with two cases. Pediatr Hematol Oncol 2021; 38:676-681. [PMID: 33784214 DOI: 10.1080/08880018.2021.1906801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- T Kaang
- Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.,Texas Children's Hospital's Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Gaborone, Botswana
| | - Maria G Dunn
- Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.,Texas Children's Hospital's Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Gaborone, Botswana.,Baylor College of Medicine, Houston, TX, USA
| | - Jeremy S Slone
- Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.,Texas Children's Hospital's Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Gaborone, Botswana.,Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
3
|
Kiwumulo HF, Muwonge H, Ibingira C, Kirabira JB, Ssekitoleko RT. A systematic review of modeling and simulation approaches in designing targeted treatment technologies for Leukemia Cancer in low and middle income countries. MATHEMATICAL BIOSCIENCES AND ENGINEERING : MBE 2021; 18:8149-8173. [PMID: 34814293 DOI: 10.3934/mbe.2021404] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Virtual experimentation is a widely used approach for predicting systems behaviour especially in situations where resources for physical experiments are very limited. For example, targeted treatment inside the human body is particularly challenging, and as such, modeling and simulation is utilised to aid planning before a specific treatment is administered. In such approaches, precise treatment, as it is the case in radiotherapy, is used to administer a maximum dose to the infected regions while minimizing the effect on normal tissue. Complicated cancers such as leukemia present even greater challenges due to their presentation in liquid form and not being localised in one area. As such, science has led to the development of targeted drug delivery, where the infected cells can be specifically targeted anywhere in the body. Despite the great prospects and advances of these modeling and simulation tools in the design and delivery of targeted drugs, their use by Low and Middle Income Countries (LMICs) researchers and clinicians is still very limited. This paper therefore reviews the modeling and simulation approaches for leukemia treatment using nanoparticles as an example for virtual experimentation. A systematic review from various databases was carried out for studies that involved cancer treatment approaches through modeling and simulation with emphasis to data collected from LMICs. Results indicated that whereas there is an increasing trend in the use of modeling and simulation approaches, their uptake in LMICs is still limited. According to the review data collected, there is a clear need to employ these tools as key approaches for the planning of targeted drug treatment approaches.
Collapse
Affiliation(s)
| | - Haruna Muwonge
- Department of Medical Physiology, Makerere University, Kampala, Uganda
| | - Charles Ibingira
- Department of Human Anatomy, Makerere University, Kampala, Uganda
| | | | | |
Collapse
|
4
|
Implementing Cancer Care in Rwanda: Capacity Building for Treatment and Scale-Up. SUSTAINABILITY 2021. [DOI: 10.3390/su13137216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: The majority of countries in sub-Saharan Africa are ill-prepared to address the rising burden of cancer. While some have been able to establish a single cancer referral center, few have been able to scale-up services nationally towards universal health coverage. The literature lacks a step-wise implementation approach for resource-limited countries to move beyond a single-facility implementation strategy and implement a national cancer strategy to expand effective coverage. Methods: We applied an implementation science framework, which describes a four-phase approach: Exploration, Preparation, Implementation, and Sustainment (EPIS). Through this framework, we describe Rwanda’s approach to establish not just a single cancer center, but a national cancer program. Results: By applying EPIS to Rwanda’s implementation approach, we analyzed and identified the implementation strategies and factors, which informed processes of each phase to establish foundational cancer delivery components, including trained staff, diagnostic technology, essential medicines, and medical informatics. These cancer delivery components allowed for the implementation of Rwanda’s first cancer center, while simultaneously serving as the nidus for capacity building of foundational components for future cancer centers. Conclusion: This “progressive scaling” approach ensured that initial investments in the country’s first cancer center was a step toward establishing future cancer centers in the country.
Collapse
|
5
|
Integration of Chronic Oncology Services in Noncommunicable Disease Clinic in Rural Rwanda. Ann Glob Health 2020; 86:33. [PMID: 32257833 PMCID: PMC7101006 DOI: 10.5334/aogh.2697] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background: In rural sub-Saharan Africa, access to care for severe non-communicable diseases (NCDs) is limited due to myriad delivery challenges. We describe the implementation, patient characteristics, and retention rate of an integrated NCD clinic inclusive of cancer services at a district hospital in rural Rwanda. Methods: In 2006, the Rwandan Ministry of Health at Rwinkwavu District Hospital (RDH) and Partners In Health established an integrated NCD clinic focused on nurse-led care of severe NCDs, within a single delivery platform. Implementation modifications were made in 2011 to include cancer services. For this descriptive study, we abstracted medical record data for 15 months after first clinic visit for all patients who enrolled in the NCD clinic between 1 July 2012 and 30 June 2014. We report descriptive statistics of patient characteristics and retention. Results: Three hundred forty-seven patients enrolled during the study period: oncology – 71.8%, hypertension – 10.4%, heart failure – 11.0%, diabetes – 5.5%, and chronic respiratory disease (CRD) – 1.4%. Twelve-month retention rates were: oncology – 81.6%, CRD – 60.0%, hypertension – 75.0%, diabetes – 73.7%, and heart failure – 47.4%. Conclusions: The integrated NCD clinic filled a gap in accessible care for severe NCDs, including cancer, at rural district hospitals. This novel approach has illustrated good retention rates.
Collapse
|
6
|
Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2019; 2019:433-442. [PMID: 31808889 PMCID: PMC6913442 DOI: 10.1182/hematology.2019000050] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Subsequent to the development and global availability of BCR/ABL-targeted tyrosine kinase inhibitors (TKIs), the prognosis of patients with chronic myeloid leukemia (CML), at least those in the chronic phase, has markedly improved, and in the developed world, the average lifespan of these patients is now close to that of age- and sex-matched subjects without the disease. However, the situation in low- and middle-income countries (LMICs) may not be so rosy. Many important differences in hematological cancers, including CML, have been highlighted in various publications in LMICs vs developed countries. These include differences in incidence and prevalence rates, age and stage of disease at diagnosis, response rates, and survival. Some of the possible reasons proposed for these are varying socioeconomic milieu (impacting availability of effective drugs and essential monitoring), environmental factors (mainly exposure to viral infections and pesticides), nutritional factors with interplay of malnutrition and diet on drug absorption and blood levels, and possible unknown genetic factors. Although generic first-generation TKIs (imatinib) are available in many parts of the world, several challenges remain in providing optimal treatment to patients with CML in resource-poor countries. Some of these include availability of optimal and high-quality BCR/ABL testing, availability and expense related to use of second- and third-generation TKIs (nilotinib, dasatinib, bosutinib, and ponatinib) and hematopoietic stem cell transplantation, issues with compliance and toxicities of drugs, and ensuring a minimal standard-of-care treatment and monitoring for every patient diagnosed with CML. For the purpose of this article, the more objective country label-LMIC-coined by the World Bank will be used (gross national income per capita between $1026 and $3995; World Bank, June 2019). Some of these issues will be discussed in this article in greater detail by experts in the field in 3 different but interconnected sections.
Collapse
MESH Headings
- Adult
- Developing Countries
- Fusion Proteins, bcr-abl/antagonists & inhibitors
- Hematopoietic Stem Cell Transplantation/economics
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/economics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Male
- Protein Kinase Inhibitors/economics
- Protein Kinase Inhibitors/therapeutic use
Collapse
Affiliation(s)
- Hemant Malhotra
- Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Jaipur, Rajasthan, India
| | | | | |
Collapse
|
7
|
Garcia-Gonzalez P, Lopes G, Schwartz E, Shulman LN. The Role of Humanitarian Donations in Decreasing Preventable Mortality From Cancer in Low-Income Countries: Models to Improve Access to Life-Saving Medicines. J Glob Oncol 2018; 4:1-3. [PMID: 30084718 PMCID: PMC6223499 DOI: 10.1200/jgo.18.00096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Pat Garcia-Gonzalez
- Pat Garcia-Gonzalez and Erin Schwartz, The Max Foundation, Seattle, WA; Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Gilberto Lopes
- Pat Garcia-Gonzalez and Erin Schwartz, The Max Foundation, Seattle, WA; Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Erin Schwartz
- Pat Garcia-Gonzalez and Erin Schwartz, The Max Foundation, Seattle, WA; Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Lawrence N. Shulman
- Pat Garcia-Gonzalez and Erin Schwartz, The Max Foundation, Seattle, WA; Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
8
|
Eniu AE, Martei YM, Trimble EL, Shulman LN. Cancer Care and Control as a Human Right: Recognizing Global Oncology as an Academic Field. Am Soc Clin Oncol Educ Book 2017; 37:409-415. [PMID: 28561681 DOI: 10.1200/edbk_175251] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The global burden of cancer incidence and mortality is on the rise. There are major differences in cancer fatality rates due to profound disparities in the burden and resource allocation for cancer care and control in developed compared with developing countries. The right to cancer care and control should be a human right accessible to all patients with cancer, regardless of geographic or economic region, to avoid unnecessary deaths and suffering from cancer. National cancer planning should include an integrated approach that incorporates a continuum of education, prevention, cancer diagnostics, treatment, survivorship, and palliative care. Global oncology as an academic field should offer the knowledge and skills needed to efficiently assess situations and work on solutions, in close partnership. We need medical oncologists, surgical oncologists, pediatric oncologists, gynecologic oncologists, radiologists, and pathologists trained to think about well-tailored resource-stratified solutions to cancer care in the developing world. Moreover, the multidisciplinary fundamental team approach needed to treat most neoplastic diseases requires coordinated investment in several areas. Current innovative approaches have relied on partnerships between academic institutions in developed countries and local governments and ministries of health in developing countries to provide the expertise needed to implement effective cancer control programs. Global oncology is a viable and necessary field that needs to be emphasized because of its critical role in proposing not only solutions in developing countries, but also solutions that can be applied to similar challenges of access to cancer care and control faced by underserved populations in developed countries.
Collapse
Affiliation(s)
- Alexandru E Eniu
- From the Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania; Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA; National Cancer Institute, Bethesda, MD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Yehoda M Martei
- From the Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania; Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA; National Cancer Institute, Bethesda, MD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Edward L Trimble
- From the Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania; Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA; National Cancer Institute, Bethesda, MD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Lawrence N Shulman
- From the Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania; Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA; National Cancer Institute, Bethesda, MD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
9
|
Increasing global access to cancer care: models of care with non-oncologists as primary providers. Lancet Oncol 2017; 18:1000-1002. [DOI: 10.1016/s1470-2045(17)30519-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 06/21/2017] [Indexed: 01/06/2023]
|